Novo Nordisk’s Wegovy (semaglutide 2.4 mg) has shown positive results in treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis in a Phase 3 trial. The drug demonstrated significant improvement in liver fibrosis compared to placebo, potentially paving the way for regulatory approval in the US and EU in the first half of 2025.